These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 19527632

  • 41. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
    Izzedine H.
    Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
    [Abstract] [Full Text] [Related]

  • 42. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.
    Shibuya M.
    BMB Rep; 2008 Apr 30; 41(4):278-86. PubMed ID: 18452647
    [Abstract] [Full Text] [Related]

  • 43. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X.
    Recent Pat Anticancer Drug Discov; 2007 Jan 30; 2(1):59-71. PubMed ID: 18221053
    [Abstract] [Full Text] [Related]

  • 44. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets.
    Rudge JS, Thurston G, Davis S, Papadopoulos N, Gale N, Wiegand SJ, Yancopoulos GD.
    Cold Spring Harb Symp Quant Biol; 2005 Jan 30; 70():411-8. PubMed ID: 16869778
    [Abstract] [Full Text] [Related]

  • 45. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.
    Adjei AA.
    Clin Lung Cancer; 2007 Feb 30; 8 Suppl 2():S74-8. PubMed ID: 17382028
    [Abstract] [Full Text] [Related]

  • 46. Unraveling galectin-1 as a novel therapeutic target for cancer.
    Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S.
    Cancer Treat Rev; 2014 Mar 30; 40(2):307-19. PubMed ID: 23953240
    [Abstract] [Full Text] [Related]

  • 47. Tumor angiogenesis and anti-angiogenic therapies.
    Shahneh FZ, Baradaran B, Zamani F, Aghebati-Maleki L.
    Hum Antibodies; 2013 Mar 30; 22(1-2):15-9. PubMed ID: 24284305
    [Abstract] [Full Text] [Related]

  • 48. Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects.
    Ferla R, Bonomi M, Otvos L, Surmacz E.
    BMC Cancer; 2011 Jul 19; 11():303. PubMed ID: 21771332
    [Abstract] [Full Text] [Related]

  • 49. [Advances of VEGF related molecular promoting tumor angiogenesis and targeting therapy].
    Guo ZY, Cao BL.
    Zhonghua Bing Li Xue Za Zhi; 2010 Apr 19; 39(4):282-4. PubMed ID: 20654135
    [No Abstract] [Full Text] [Related]

  • 50. Antiangiogenic agents in cancer therapy.
    Lenz HJ.
    Oncology (Williston Park); 2005 Apr 19; 19(4 Suppl 3):17-25. PubMed ID: 15934499
    [Abstract] [Full Text] [Related]

  • 51. Antiangiogenesis, anti-VEGF(R) and outlook.
    Petersen I.
    Recent Results Cancer Res; 2007 Apr 19; 176():189-99. PubMed ID: 17607926
    [Abstract] [Full Text] [Related]

  • 52. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H, Niclou SP, Johansson M, Bjerkvig R.
    Expert Opin Ther Targets; 2009 Apr 19; 13(4):455-68. PubMed ID: 19335067
    [Abstract] [Full Text] [Related]

  • 53. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.
    Murukesh N, Dive C, Jayson GC.
    Br J Cancer; 2010 Jan 05; 102(1):8-18. PubMed ID: 20010945
    [Abstract] [Full Text] [Related]

  • 54. Mode of action and clinical impact of VEGF signaling inhibitors.
    Soltau J, Drevs J.
    Expert Rev Anticancer Ther; 2009 May 05; 9(5):649-62. PubMed ID: 19445581
    [Abstract] [Full Text] [Related]

  • 55. [Anti-angiogenic strategies in glioblastoma].
    Guillamo JS.
    Rev Neurol (Paris); 2011 Oct 05; 167(10):662-7. PubMed ID: 21889779
    [Abstract] [Full Text] [Related]

  • 56. Antibody-based antiangiogenic and antilymphangiogenic therapies to prevent tumor growth and progression.
    Bzowska M, Mężyk-Kopeć R, Próchnicki T, Kulesza M, Klaus T, Bereta J.
    Acta Biochim Pol; 2013 Oct 05; 60(3):263-75. PubMed ID: 23819129
    [Abstract] [Full Text] [Related]

  • 57. Targeting VEGF/VEGFR in the treatment of psoriasis.
    Li W, Man XY, Chen JQ, Zhou J, Cai SQ, Zheng M.
    Discov Med; 2014 Sep 05; 18(98):97-104. PubMed ID: 25227750
    [Abstract] [Full Text] [Related]

  • 58. [VEGF in neoplastic angiogenesis].
    Chekhonin VP, Shein SA, Korchagina AA, Gurina OI.
    Vestn Ross Akad Med Nauk; 2012 Sep 05; (2):23-33. PubMed ID: 22642175
    [Abstract] [Full Text] [Related]

  • 59. Cancer. Encouraging results for second-generation antiangiogenesis drugs.
    Marx J.
    Science; 2005 May 27; 308(5726):1248-9. PubMed ID: 15919970
    [No Abstract] [Full Text] [Related]

  • 60. VEGF/VEGFR signalling as a target for inhibiting angiogenesis.
    Kiselyov A, Balakin KV, Tkachenko SE.
    Expert Opin Investig Drugs; 2007 Jan 27; 16(1):83-107. PubMed ID: 17155856
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.